ARS Pharmaceuticals replaces CEO, names Donn Casale to top job
The board installed President Donn Casale as CEO effective immediately, ousting Richard Lowenthal without cause.
ARS Pharmaceuticals, Inc. disclosed in a Form 8-K dated July 6, 2026 that its Board of Directors moved to change chief executive leadership. On July 7, 2026, the board appointed the company's current President Donn Casale as Chief Executive Officer, effective immediately, replacing Richard Lowenthal in that role.1
Alongside the CEO change, Casale was also named to the board as a Class III director, with a term running to the company's 2029 annual stockholders meeting.1
Regarding Lowenthal's departure, the filing states that he was informed on July 6, 2026 that his employment was ending without cause, effective right away.1
The company did not restate Casale's professional background in this filing. Instead, it pointed to biographical details already disclosed in an earlier Form 8-K filed with the SEC on May 13, 2026, which it incorporated by reference.1
The 8-K was signed on July 7, 2026 by Casale in his new capacity as President and Chief Executive Officer, serving as the company's principal executive officer. ARS Pharmaceuticals trades on the Nasdaq Stock Market under the ticker SPRY. The filing did not include additional detail on the reasons behind the leadership change or on any severance or transition terms for Lowenthal.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.